Laurus Labs Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Laurus Labs Ltd trades at ₹1,969, in a confirmed uptrend and 141 weeks into that stage. That is +44.0% against its own 200-day average. It sits at 100% of a 52-week range of ₹930 to ₹1,969. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 37 straight weeks.

Today the stock is in a confirmed uptrend — week 141 of stage 2, confirmed. At ₹1,969 it trades +44.0% versus its 200-day average and sits at 100% of its 52-week range (₹930–₹1,969).

Against the market, two honest reads. Cumulative: over the last 9.7 years the stock moved +1,970% while the NIFTY 500 moved +234% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 37 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Laurus Labs Ltd trades at 97.3× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 33.9×, measured across 9.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 97.3× is at the pricey end of its own range (86th percentile), against a long-run median of 33.9× measured over 9.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +147.9% against a +119.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +24.6%/yr price move, ~+0.6%/yr came from earnings growth and ~+24.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Laurus Labs Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +318.4% at its peak to +114.6% but is still expanding, ROCE holding at 9.4%. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

4-Factor Sector Score

71.2/100 — rank 4 of 24 in Pharma - API & CRAMS · 93% evidence confidence

Laurus Labs Ltd scores 71.2 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 4. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

The four contributions add to the total exactly: 32.2 + 18.2 + 5.3 + 15.5 = 71.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Laurus Labs Ltd reported ₹2,026 Cr of revenue in the Jun 26 quarter, +29.0% year on year. That is the 7th straight quarter of year-on-year growth. Over 10 years it has compounded at 14.4% a year. The last full year, FY26, came in at ₹6,813 Cr. The last four reported quarters add to ₹7,269 Cr.

FY26 revenue came in at ₹6,813 Cr (+22.7% on the year), capping 10 years at 14.4% compound. The latest quarter (Jun 26) printed ₹2,026 Cr, +29.0% year on year — the 7th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +23.8% growth against the decade's 14.4% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +22.6% over the last 4 quarters against +19.9%/yr over the last 8 — stabilising; TTM profit +114.6% vs +171.4%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Laurus Labs Ltd's operating margin is 32.0% in the Jun 26 quarter, +8.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0% to 32.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 32.0%, +8.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0%–32.0%.

Why the margin moved: operating margin went +7.1 pp year on year while gross margin went +3.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Laurus Labs Ltd earned ₹362 Cr of net profit in the Jun 26 quarter, +123.5% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹890 Cr. The 10-year compound rate is 20.8%. That is 17.9% of the quarter's revenue. The same quarter a year earlier earned ₹162 Cr.

Jun 26 profit was ₹362 Cr, +123.5% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹890 Cr (+148.6%), and the 10-year compound rate is 20.8%.

Why profit moved: revenue contributed +29.0% and the margin +8.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +296.4% vs revenue +23.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 205% of Laurus Labs Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,624 Cr of operating cash against ₹890 Cr of profit. After ₹1,043 Cr of capital spending, ₹581 Cr was left as free cash.

FY26: operating cash of ₹1,624 Cr against reported profit of ₹890 Cr, leaving free cash of ₹581 Cr after ₹1,043 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 205% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 205%: the cash cycle stretched 97 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Laurus Labs Ltd's cash conversion cycle runs 263 days in FY26, up from 166 days in FY21. Capital spending ran ₹2,479 Cr over the last 3 years. At FY26 sales of ₹6,813 Cr each day of that cycle holds about ₹18.7 Cr, so roughly ₹4,909 Cr sits inside the business at any moment.

FY26: debtors at 115 days, inventory at 317 days — roughly 10.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 263 days, looser than FY21's 166.

The full loop: cash goes out to suppliers and production on day 0; stock waits 317 days to sell; customers pay about 115 days after that; and suppliers themselves are paid at 170 days — netting out to the 263-day cycle.

In money terms: at FY26 sales of ₹6,813 Cr, each day of the cycle holds about ₹18.7 Cr — so the 263-day loop keeps roughly ₹4,909 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹2,479 Cr over the last 3 fiscal years against ₹1,295 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹773 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Laurus Labs Ltd earns a ROCE of 18% in FY26. That is up from a trough of 7% in FY24. Return on invested capital clears the cost of that capital by +3.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.1% net margin on 0.65× asset turns.

FY26 ROCE is 18%, recovered from a FY24 trough of 7% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 13.1% net margin × 0.65× asset turns × 1.98× balance-sheet leverage ≈ 16.9% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 15.0% − 12.0% = a +3.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Laurus Labs Ltd carries total debt of ₹2,518 Cr against shareholder equity of ₹5,431 Cr as of Jun 26, a debt-to-equity of 0.46. On the annual view that ratio went from 0.53 in FY22 to 0.46 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of ₹2,518 Cr against shareholder equity of ₹5,431 Cr — a debt-to-equity of 0.46. On the annual view, debt-to-equity went from 0.53 (FY22) to 0.46 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 2.3 points of Laurus Labs Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 28.0% of the company. Promoters moved +0.3 points over the same window, to 27.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +2.3 points over 8 quarters to 28.0%; Promoters: +0.3 points over 8 quarters to 27.5%; Domestic institutions: +0.2 points over 8 quarters to 13.7%.

Why the register moved: foreign institutions drove it (+2.3 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Laurus Labs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions